The COVID-19 pandemic challenged the in vitro diagnostic business to quickly scale a novel assay and get closer to the point of use in airports, schools, workspaces, and more. Point-of-care diagnostics present a unique opportunity in the decentralization of healthcare.
To win the attention of investors and get traction in the market, developers must deliver a platform that is differentiated. It needs to be optimized for a more distributed point-of-care environment and provide a broad range of assays with highly actionable results. At the same time, it’s important to move quickly, as time to market is critical.
This white paper from Invetech discusses important strategies for ensuring point-of-care diagnostic platforms deliver a great user experience, the emerging technologies that are paving the way for breakthroughs in point-of-care platforms, and proven approaches for minimizing total cost of ownership.
Offered Free by: Invetech
See All Resources from: Invetech